Is Novavax, Inc. overvalued?

Novavax, Inc. (NVAX) — key valuation metrics and fundamentals.

No verdict

Price

$8.53

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$1.41B

Dividend yield

0.0%

Return on equity

45.1%

Sector

Healthcare

Fair value compares NVAX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.

Related stocks